The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

As per The Business Research Company’s Typhoid Vi Polysaccharide Vaccine Global Market Report 2023, the typhoid Vi polysaccharide vaccine market is expected to show significant growth in the forecast period.

The global typhoid Vi polysaccharide vaccine market is undergoing a remarkable surge, with the market size set to leap from $4.23 billion in 2022 to an anticipated $4.96 billion in 2023, boasting a compound annual growth rate (CAGR) of 17.3%. Projections for the future are even more promising, with the market size expected to reach $9.20 billion in 2027, sustaining a robust CAGR of 16.7%. What fuels this impressive growth? Let’s delve into the key drivers and trends shaping the landscape of typhoid prevention.

Rising Typhoid Prevalence: A Catalyst for Market Growth

The prevalence of typhoid, a potentially fatal infection caused by Salmonella typhi bacteria, is on the rise globally. Typically transmitted through contaminated food or drink, typhoid poses a significant health risk. In March 2021, the Centers for Disease Control and Prevention (CDC) reported that Salmonella Typhi infections affected around 5,700 Americans annually, leading to approximately 620 hospitalizations. On a global scale, typhoid fever accounts for 11 to 21 million cases each year, with a staggering 200,000 fatalities. In response to this growing threat, the typhoid Vi polysaccharide vaccine emerges as a crucial tool for immunizing individuals aged 2 and above against the perils of typhoid fever.

Major Players Shaping the Market Landscape

Key players play a pivotal role in steering the trajectory of the typhoid Vi polysaccharide vaccine market. Companies such as Sanofi Pasteur SA, GlaxoSmithKline plc, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, EMERGENT, PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, and Mylan N.V. contribute significantly to the industry’s growth and development.

Strategic Partnerships: A Rising Trend

In the dynamic landscape of the typhoid Vi polysaccharide vaccine market, strategic partnerships are gaining prominence. Major companies are recognizing the importance of collaboration to fortify their positions in the market. Notable instances include the partnership between The International Vaccine Institute and Moderna in July 2022. This collaboration resulted in the development of the world’s first affordable oral cholera vaccine and a groundbreaking new-generation typhoid conjugate vaccine. Similarly, Biological E, based in India, teamed up with the GSK Vaccines Institute for Global Health in December 2020 to work on the development of a typhoid conjugate vaccine (TCV). These strategic alliances underscore the industry’s commitment to innovation and global health.

Market Segmentation for Tailored Solutions

The typhoid Vi polysaccharide vaccine market is strategically segmented to cater to diverse needs:

1. By Type:
   • Child
   • Adult
2. By Route of Administration:
   • Oral
   • Parenteral
3. By Application:
   • Government Institutions
   • Private Sector
   • Other Applications

Asia-Pacific Leading the Charge

In 2022, Asia-Pacific emerged as the largest region in the typhoid Vi polysaccharide vaccine market. This regional dominance can be attributed to factors such as increasing awareness, strategic healthcare initiatives, and a proactive approach to preventive healthcare.

View More On The Typhoid Vi Polysaccharide Vaccine Market Report 2023 – https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Request A Sample Of The Global Typhoid Vi Polysaccharide Vaccine Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=8313&type=smp

The Typhoid Vi Polysaccharide Vaccine Global Market Report 2023  provides an in-depth analysis on the typhoid Vi polysaccharide vaccine market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the typhoid Vi polysaccharide vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. 

View More Related Reports –
Pediatric Vaccine Global Market Report 2023
Veterinary Vaccines Global Market Report 2023
Companion Animal Veterinary Vaccines Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/ 
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company 
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model